Importantly, the phenotypic and clinical specifics of these patients recently led to the proposal of MDS with low blasts and an SF3B1 mutation (MDS‐SF3B1) as a new MDS sybtype [1]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.